Keep in mind that every single trade on the market has an equal and opposite opinion. On CLS, we would not consider 24X earnings, for a company with a strong balance sheet and good growth, to be excessively valued. The article talks largely about margins and 'moat' and R&D. Margins have been improving. It may not have a strong moat such as, say NVDA, but its customer relationships are strong and it is tied into some very strong growth companies. While demand is high, it is 'needed' by its customers. The low R&D spend is a valid concern, but this may change as CLS gets more involved with creating products rather than just being an out-sourcer. We are fine with some insider selling for a stock up 127% over one year. Insiders can sell some and still have more dollars at risk than they did a year ago. April of course is also tax time and some selling in the spring is quite common.
Authors of this answer, directors, partners and/or officers of 5i Research and/or affiliated companies have a financial or other interest in NVDA.